DRTX

Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

[at noodls] – Download PDF Study Meets Primary Endpoint Conference Call and Webcast Today at 9:00 A.M. ET to Discuss Results CHICAGO– Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results … moreView todays social media effects on DRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Durata is hiring next, click here to view […]

Durata Therapeutics to Host Conference Call and Webcast on December 11, 2012 at 9:00AM ET to Present Preliminary Top-line Results from its DISCOVER 1 Study

[at noodls] – Download PDF CHICAGO– Durata Therapeutics, Inc.(NASDAQ: DRTX) today announced that it will host a conference call and webcast at 9:00am Eastern Time on Tuesday, December 11, 2012 to present preliminary … moreView todays social media effects on DRTXView the latest stocks trending across Twitter. Click to view dashboardSee who Durata is hiring next, click here to view […]

Durata Therapeutics Relocating Corporate Headquarters to Chicago

[at noodls] – Download PDF MORRISTOWN, N.J & CHICAGO–(BUSINESS WIRE)–Durata Therapeutics, Inc. (NASDAQ: DRTX) is working with the Illinois Department of Commerce and Economic Opportunity to relocate Durata’s corporate … moreView todays social media effects on DRTXView the latest stocks trending across Twitter. Click to view dashboard […]

FDA Designates Durata Therapeutics’ Dalbavancin a Qualified Infectious Disease Product (QIDP)

[at noodls] – Download PDF Agency’s Action Expedites Regulatory Review Process and Extends Dalbavancin’s Exclusivity Period Upon NDA Approval MORRISTOWN, N.J.–(BUSINESS WIRE)–Durata Therapeutics (NASDAQ: DRTX) today … moreView todays social media effects on DRTXView the latest stocks trending across Twitter. Click to view dashboard […]